The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.
A talk discusses the challenges of single-cell data analysis, such as feature sparsity and the effects of rare cells. AI/ML strategies are uniquely positioned to model this data. ImYoo, a startup founded in 2021, is applying single-cell model architectures for unsupervised discovery of patient groupings and predicting sample-level phenotypical data in autoimmune disease. Why it matters: This highlights the growing application of AI/ML in analyzing single-cell data for population-scale human health studies, an area ripe for innovation and improvement in the Middle East's growing biotech sector.
KAUST, Tufts, and JIHS researchers created pangenome graphs using Saudi and Japanese samples, named JaSaPaGe. These graphs address the underrepresentation of these populations in existing pangenome databases, which are used as references for understanding individual DNA. The population-specific pangenomes are expected to improve variant calling and diagnostic accuracy for genetic disorders in these groups. Why it matters: This work promotes precision medicine and reduces diagnostic gaps for underrepresented populations by providing more relevant genetic baselines.
Eduardo da Veiga Beltrame, bioinformatics lead at ImYoo (a Caltech spinout), presented on scalable methods for single-cell omics data analysis, including kallisto|bustools and scvi-tools. He highlighted their use in ImYoo's decentralized longitudinal study on Inflammatory Bowel Disease (IBD), where patients self-collect capillary blood samples. Beltrame also discussed his research on STEM education programs in Brazil as a visiting scholar at UC Berkeley. Why it matters: This highlights the growing trend of decentralized clinical studies leveraging advanced single-cell technologies for precision medicine, showcasing the potential of remote data collection and analysis in understanding complex diseases.
MBZUAI's Eduardo da Veiga Beltrame is developing machine learning tools for analyzing single-cell RNA sequencing data, which measures RNA in thousands of individual cells. Sequencing costs have decreased faster than Moore's Law, enabling large-scale data collection in biology. RNA sequencing provides insights into gene expression and cellular activity, crucial for personalized medicine. Why it matters: Advancements in single-cell RNA sequencing and ML analysis will accelerate personalized medicine by providing detailed insights into cellular mechanisms and disease pathways.